Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2001
Business Overview: The Company operates in two segments: Animal Health Products and Research & Development (R&D). Its primary customers are in the U.S. dairy and beef industries. Key products include FIRST DEFENSE(R), KAMAR(R) HEATMOUNT(R) DETECTOR, and WIPEOUT(R) DAIRY WIPES.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2000 | 3 Months Ended Sep 30, 2001 | 3 Months Ended Sep 30, 2000 |
|---|---|---|---|---|
| Total Revenues | $4,713,073 | $4,043,489 | $1,387,697 | $1,137,584 |
| Net Profit (Loss) | $164,995 | $277,965 | $(56,543) | $(13,483) |
| Net Profit Per Share (Basic) | $0.06 | $0.11 | $(0.02) | $(0.01) |
| Cash and Equivalents (Ending) | $1,369,679 | $1,940,531 | $1,369,679 | $1,895,149 |
| Operating Cash Flow | $295,332 | $(123,111) | N/A | N/A |
| Total Debt (Current + Long Term) | $419,487 | $434,659 | $419,487 | $434,659 |
| Gross Margin % (Product Sales) | 48% | 50% | 44% | 47% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 17% ($670,000) for the nine-month period and 22% ($250,000) for the quarter compared to the prior year. Product sales drove this growth, increasing 15% year-over-year for the nine months.
- Profitability Decline: Despite revenue growth, net profit for the nine months decreased by approximately $113,000 compared to the prior year. This was primarily due to a $123,000 tax expense in the current period, whereas no tax expense was recorded in the comparable 2000 period.
- Quarterly Loss: The Company reported a net loss of $56,543 for the quarter ended September 30, 2001, compared to a loss of $13,483 in the same period in 2000.
- Expense Increases: Sales and marketing expenses rose significantly (38% for nine months, 52% for the quarter) to support new product launches and address a sales backlog. R&D expenses decreased 8% for the nine-month period.
- Investing Activity: Net cash used for investing activities increased to $871,493 (from $64,604 in 2000) due to a facility addition ($650,000) and new manufacturing equipment ($250,000) to increase production capacity.
Guidance, Outlook, and Risks
- Production Backlog: A backlog of orders for FIRST DEFENSE(R) valued at approximately $1,100,000 as of September 30, 2001, negatively impacted sales recognition. Management intends to significantly reduce this backlog by year-end following a facility expansion completed in May 2001.
- R&D Focus: The Company targets investing 10% to 13% of product sales in R&D (net of grants/licensing). Significant investment is being made in MAST OUT(TM), a mastitis treatment requiring FDA approval, which may temporarily impact quarterly profitability.
- Liquidity: Cash and cash equivalents decreased by $525,000 during the period. Management believes current capital resources are sufficient to meet working capital requirements for the next twelve months.
- Regulatory Risks: Sales of TIP-TEST(TM): JOHNE'S are currently limited by state regulatory barriers. Future profitability depends on regulatory approvals for new products like MAST OUT(TM).
- Deferred Revenue: $208,000 is recorded as deferred revenue from technology licensing and grants, to be recognized over future periods.
Investor Verification Checklist
- Backlog Resolution: Verify if the $1.1 million backlog of FIRST DEFENSE(R) orders was successfully fulfilled and recognized as revenue by year-end 2001.
- MAST OUT(TM) Progress: Monitor the status of FDA approval and clinical trials for the MAST OUT(TM) product, given the high investment costs and regulatory hurdles.
- Cash Burn vs. Operating Cash Flow: Assess the sustainability of the $525,000 cash decrease against the positive operating cash flow of $295,332, considering future capital expenditure needs.
- Regulatory Barriers: Confirm progress in overcoming state regulatory barriers for TIP-TEST(TM): JOHNE'S to unlock potential revenue growth.
- Debt Maturity: Review the repayment schedule for the 8.62% bank mortgage, with a significant principal payment of approximately $392,000 due in 2003.